// App-Quantinova.ai

TPS2630 : A phase 1 dose-escalation study of EC1456, a folic acid-tubulysin small-molecule drug conjugate, in adult patients (pts) with advanced solid tumors.

Researchers

Presenter

  • Wael A. Harb

Principal Investigators

  • Ramesh K. Ramanathan

  • Daniela E. Matei

  • Binh Nguyen

  • Edward A. Sausville

Medical Centers

  • Virginia G. Piper Cancer Center at Honor Health/TGen, Scottsdale, AZ

  • Endocyte, Inc., West Lafayette, INUniversity of Maryland Medical Center, Baltimore, MDIndiana University, Indianapolis, IN

  • Horizon Oncology Center, Lafayette, IN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Technetium Tc99m etarfolatide

  • FA-8

  • tubulysin

  • EC1456

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • I

Study Id's

  • NCT01999738

Sponsors

  • Endocyte

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved